Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

OBJECTIVE: To estimate the budget impact of introducing avelumab as a second-line (2L) treatment option for patients with locally advanced or metastatic urothelial cancer (mUC) from the perspective of a US third-party payer (commercial and Medicare). METHODS: A budget impact model (BIM) with a three...

Descripción completa

Detalles Bibliográficos
Autores principales: Kongnakorn, Thitima, Bharmal, Murtuza, Kearney, Mairead, Phatak, Hemant, Benedict, Agnes, Bhanegaonkar, Abhijeet, Galsky, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850681/
https://www.ncbi.nlm.nih.gov/pubmed/31807039
http://dx.doi.org/10.2147/CEOR.S215069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850681/
https://www.ncbi.nlm.nih.gov/pubmed/31807039
http://dx.doi.org/10.2147/CEOR.S215069

Ejemplares similares